Creation of the Owen dermatology company in Dallas, Texas, USA.
	Acquisition of Owen by ophthalmology specialist Alcon, headquartered in Fort Worth, Texas.
	Nestlé acquires Alcon to strengthen its presence in the North American market.
	L'Oréal creates its International Dermatology Research Center (CIRD) in Sophia-Antipolis, France, specializing in fundamental research into skin physiology.
	Nestlé and L'Oréal form a joint venture to become the world’s leading dermatology player. Galderma is born.
	Galderma’s first affiliate opens for business in France, followed by a second in Italy. The International Dermatology Research Center focuses its efforts on prescription dermatology products.
	Galderma progressively takes over Alcon’s dermatology business, allowing it to focus exclusively on ophthalmology.
	Global organization implemented and new affiliates opened in Canada, Germany, Spain and the United Kingdom.
	Acquisition of MetroGel®/Rozex® to include rosacea treatments in the product portfolio.
	Galderma inaugurates its wholly-owned production plant in Alby-sur-Chéran, near Annecy in the French Alps.
	Launch of anti-acne treatment Differin®, Galderma’s first home-grown dermatology product.
	Acquisition of a plant belonging to Wyeth-Ayerts in Montreal, Canada, to develop a state-of-the-art manufacturing plant.
	Acquisition of Basotherm, a subsidiary of Germany’s Boehringer.
	Inauguration of a new R&D facility in Princeton, New Jersey, USA. Acquisition in Brazil of Darrow’s dermatology portfolio.
	Acquisition of Loceryl® (fungal nail infections), developed by Laboratoires Roche, together with the Scandinavian dermatology portfolio developed by Nycomed.
	The Montreal production unit comes on stream. Launch of Silkis® (psoriasis) and acquisition of Capex® Shampoo (seborrheic dermatitis).
	Licensing agreement for Metvix® (precancerous skin lesions and skin cancer treatment). Launch of Clindagel® (anti-acne).
	Foundation stone laid for the new Research & Development Center in Sophia-Antipolis, France. Licensing agreements for Tri-Luma® (melasma or mask of pregnancy) and Pekiron® (Loceryl® Cream) in Japan. First FDA approvals for pharmaceutical production in Montreal.
	Launch of Metvix® in Germany and the UK and Clobex® Lotion (inflammatory skin conditions) in the US.
	Opening of a new production site in Hortolandia, Brazil. Clobex® Shampoo launch in the United-States and acquisition of Tri-Luma®.
	Metrogel® 1% (rosacea) launch in the United-States. Galderma ranks Number One in D class in its markets (source : IMS Health, IMS dataview - D class - MAT Q3 2005 - 33 countries).
	Clobex® Spray launch in the US. Opening of the new R&D center in Sophia Antipolis, France.
	In-licensing of Ipsen's Botulinum Toxin Type A for Europe, Argentina and Brazil. Differin® 0.3% launch. License agreements for Pliaglis® (topical anesthetic).
	Launch of Pliaglis®  and Epiduo®  (acne).
	Launch of Azzalure® (glabella lines) and Oracea® in Europe. Vertical®(psoriasis) launch in the United States.
	Differin® Lotion 0.1% (acne) launch in the United States.

	Creation of the Owen dermatology company in Dallas, Texas, USA.
	Acquisition of Owen by ophthalmology specialist Alcon, headquartered in Fort Worth, Texas.
	Nestlé acquires Alcon to strengthen its presence in the North American market.
	L'Oréal creates its International Dermatology Research Center (CIRD) in Sophia-Antipolis, France, specializing in fundamental research into skin physiology.
	Nestlé and L'Oréal form a joint venture to become the world’s leading dermatology player. Galderma is born.
	Galderma’s first affiliate opens for business in France, followed by a second in Italy. The International Dermatology Research Center focuses its efforts on prescription dermatology products.
	Galderma progressively takes over Alcon’s dermatology business, allowing it to focus exclusively on ophthalmology.
	Global organization implemented and new affiliates opened in Canada, Germany, Spain and the United Kingdom.
	Acquisition of MetroGel®/Rozex® to include rosacea treatments in the product portfolio.
	Galderma inaugurates its wholly-owned production plant in Alby-sur-Chéran, near Annecy in the French Alps.
	Launch of anti-acne treatment Differin®, Galderma’s first home-grown dermatology product.
	Acquisition of a plant belonging to Wyeth-Ayerts in Montreal, Canada, to develop a state-of-the-art manufacturing plant.
	Acquisition of Basotherm, a subsidiary of Germany’s Boehringer.
	Inauguration of a new R&D facility in Princeton, New Jersey, USA. Acquisition in Brazil of Darrow’s dermatology portfolio.
	Acquisition of Loceryl® (fungal nail infections), developed by Laboratoires Roche, together with the Scandinavian dermatology portfolio developed by Nycomed.
	The Montreal production unit comes on stream. Launch of Silkis® (psoriasis) and acquisition of Capex® Shampoo (seborrheic dermatitis).
	Licensing agreement for Metvix® (precancerous skin lesions and skin cancer treatment). Launch of Clindagel® (anti-acne).
	Foundation stone laid for the new Research & Development Center in Sophia-Antipolis, France. Licensing agreements for Tri-Luma® (melasma or mask of pregnancy) and Pekiron® (Loceryl® Cream) in Japan. First FDA approvals for pharmaceutical production in Montreal.
	Launch of Metvix® in Germany and the UK and Clobex® Lotion (inflammatory skin conditions) in the US.
	Opening of a new production site in Hortolandia, Brazil. Clobex® Shampoo launch in the United-States and acquisition of Tri-Luma®.
	Metrogel® 1% (rosacea) launch in the United-States. Galderma ranks Number One in D class in its markets (source : IMS Health, IMS dataview - D class - MAT Q3 2005 - 33 countries).
	Clobex® Spray launch in the US. Opening of the new R&D center in Sophia Antipolis, France.
	In-licensing of Ipsen's Botulinum Toxin Type A for Europe, Argentina and Brazil. Differin® 0.3% launch. License agreements for Pliaglis® (topical anesthetic).
	Launch of Pliaglis®  and Epiduo®  (acne).
	Launch of Azzalure® (glabella lines) and Oracea® in Europe. Vertical®(psoriasis) launch in the United States.
	Differin® Lotion 0.1% (acne) launch in the United States.